With the demand for cell and gene therapies mounting, CDMO Cognate BioServices is looking to swiftly expand its U.S. headquarters with two new facilities—and it's not stopping there. Its dedicated ...
Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, began a multi-phase augmentation of its plasmid DNA services as a continuation of its gene therapy services’ expansion ...
(RTTNews) - Charles River Laboratories International, Inc. (CRL) reported fourth-quarter earnings per share on a non-GAAP basis of $2.39, an increase of 18.9% from last year. On average, 16 analysts ...
Cognate BioServices' facility at 4600 E. Shelby Drive in Memphis Lisa Buser Photography To continue reading this content, please enable JavaScript in your browser ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier ...
Cognate’s revenue for 2021 is projected at $140 million with the potential to grow 25% annually over the next five years. Memphis firm’s Cobra division helping develop COVID-19 vaccines Memphis ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc.
Charles River Laboratories plans to acquire the cell and gene therapy contract development and manufacturing organization (CDMO) Cognate BioServices for approximately $875 million cash, in a deal that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results